BSETrident Lifeline Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 3 Feb, 2026 · 17:44 IST

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rupaben Chetan Jariwala

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.1%Next day
₹290.25
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+1.8% vs market
Pharmaceuticals peers, median of 156sector-0.4%+2.5% vs sector

By the next day the stock moved 1.8 pts more than Nifty Microcap 250 and 2.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
—+1.3—+0.2—
Next day
+2.1+0.3+1.8-0.4+2.5
2d
—-0.5—-1.1—
3d
-2.5+2.1-4.6+0.7-3.2
4d
+0.6+3.1-2.5+1.3-0.7
5d
-6.8+2.6-9.4+1.5-8.3
1w
-3.9+0.6-4.5+0.3-4.2
15d
-11.1-1.4-9.7-2.3-8.8
1m
—-6.9—-5.1—
2m
-12.5-7.7-4.8-7.9-4.6
3m
-13.7+7.0-20.6+0.8-14.5
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Rupaben Chetanbhai Jariwala, a promoter of Trident Lifeline Limited, filed a disclosure under SEBI's Takeover Regulations for an open market sale of 15,600 equity shares on 02 February 2026. This represents 0.13% of the company's total share/voting capital. Her holding declined from 7,18,300 shares (6.02%) to 7,02,700 shares (5.89%) as a result. The transaction was carried out on BSE, and the company's equity share capital stands at Rs. 11.93 crore (1,19,33,000 shares of Rs. 10 each), with diluted share capital at Rs. 12.49 crore.

Likely market impact

The sale is small in size (0.13%) and unlikely to materially affect the stock price, though it is a minor reduction in promoter holding worth tracking alongside other insider activity.